Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin

Retrospective analysis (n=134) reported non-significant clinical improvement on day 7 in 26.8% of 82 pts who received hydroxychloroquine and azithromycin. Treated pts had significantly higher 28-day mortality vs untreated pts (p=0.03) and higher risk of QT prolongation.

British Journal of Clinical Pharmacology